- About Us
- Services & Solutions
- Bioconjugation Discovery
- Bioconjugation Process Development
- Analytical Development
- Formulation and DP Development
- GMP mAb Intermediate and Conjugation Manufacturing
- GMP Formulation, Fill and Lyophilization
- Payload and Linker R&D and Manufacturing
- Ready-Made Payloads & Linkers
- Novel Technology Platform
- Investor Relations
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
WuXi XDC Announces Ground-breaking on Singapore Manufacturing Facility to Empower Global Bioconjugates Development
Shanghai, China, and Singapore, March 19, 2024—WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugates market, today announced a ground-breaking of manufacturing...WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development
SHANGHAI, Jan 31, 2024—WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clinical stage biotechnology company renowned for...
WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs)
Shanghai, China, and Incheon, South Korea, Jan.24, 2024—WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltrion, Inc. (068270.KS), a leading...WuXi XDC Congratulates OnCusp Therapeutics on Series A Financing to Expedite Portfolio of Assets for Cancer Patients
Shanghai, January 15th, 2024 – WuXi XDC（2268.HK）, a leading Contract Research, Development, and Manufacturing Organization (CRDMO) focused on ADC and other types of bioconjugates market, congratulates OnCusp Therapeutics on the completion of $100 million Series A...Dr. Jimmy Li, CEO of WuXi XDC, delivered a keynote speech entitled “Global Premier Bioconjugation CRDMO to Enable and Expedite Innovations” at 42nd Annual J.P. Morgan Healthcare Conference
JPM医疗健康年会 | 药明合联李锦才博士：全球领先的生物偶联药CRDMO加速赋能行业创新发展 美国旧金山当地时间1月9日上午，在摩根大通第42届年度医疗健康大会现场，药明合联（WuXi XDC，2268.HK）CEO李锦才博士应邀出席大会并发表了题为“全球领先的生物偶联药CRDMO加速赋能行业创新发展”的主题演讲，通过现场以及在线直播的方式和全球医疗健康行业专家和投资机构连线，分享了药明合联最新的业务动态，生物偶联药行业的前沿洞察，以及未来展望。 全球领先的生物偶联药CRDMO：加速药物发现、开发和商业化生产...
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?